

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BIGHAM MICHAEL <hr/> (Last) (First) (Middle) C/O ABINGWORTH MANAGEMENT INC 890 WINTER STREET, SUITE 150 <hr/> (Street) WALTHAM MA 02451 <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol SUPERNUS PHARMACEUTICALS INC [SUPN]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 03/20/2013	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/20/2013		P		5,000	A	\$5.172 ⁽¹⁾	5,000	I	By Beatrice Emerson Bigham Trust U/A DTD 2/28/2001
Common Stock	03/20/2013		P		5,000	A	\$5.195 ⁽²⁾	5,000	I	By Cabot Forbes Bigham Trust U/A DTD 10/11/1996
Common Stock	03/20/2013		P		10,000	A	\$5.264 ⁽³⁾	10,000	I	By Michael F Bigham CRUT U/A DTD 11/23/1994
Common Stock	03/22/2013		P		15,000	A	\$5.653 ⁽⁴⁾	25,000	I	By Michael F Bigham CRUT U/A DTD 11/23/1994

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Director Stock Option (Right to Buy)	\$7.9							02/05/2014	02/05/2023	Common Stock	8,722	8,722	D	

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$5.11 to \$5.20, inclusive. The Reporting Person undertakes to provide to any security holder of Supemus Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) through (4).
2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from \$5.17 to 5.20, inclusive.
3. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from \$5.18 to 5.49, inclusive.
4. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from \$5.53 to 5.68, inclusive.

/s/ Gregory S. Patrick, as
attorney-in-fact 03/26/2013

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.